DTx Pharma
About DTx Pharma
DTx Pharma develops RNA-based therapeutics using its FALCON platform, which conjugates short interfering RNAs with fatty acids to enhance cellular uptake and biodistribution beyond the liver. The company targets rare peripheral nervous system, muscle, and CNS disorders, expanding treatment options for previously untreatable genetic conditions.
```xml <problem> Delivery of RNA therapeutics to tissues beyond the liver remains a significant challenge, limiting the treatment of genetic diseases affecting the peripheral nervous system, muscle, and central nervous system. Existing RNA delivery methods often struggle with effective cellular uptake and biodistribution to these target tissues. </problem> <solution> DTx Pharma utilizes its proprietary FALCON (Fatty Acid Ligand Conjugated OligoNucleotides) platform to overcome the limitations of extra-hepatic RNA delivery. The FALCON platform conjugates short interfering RNAs (siRNAs) with fatty acids, enhancing cellular uptake and biodistribution to target tissues beyond the liver. This approach expands the therapeutic potential of RNA medicines, enabling the treatment of previously inaccessible genetic disorders affecting the peripheral nervous system, muscle, and central nervous system. By improving siRNA delivery, DTx Pharma aims to develop novel therapeutics for rare and untreatable diseases. </solution> <features> - FALCON platform: Conjugates siRNAs with fatty acids for enhanced cellular uptake and biodistribution. - Targets peripheral nervous system, muscle, and CNS disorders. - siRNA design expertise for optimal therapeutic effect. </features> <target_audience> The primary target audience includes patients suffering from rare, previously untreatable genetic disorders affecting the peripheral nervous system, muscle, and central nervous system. </target_audience> ```
What does DTx Pharma do?
DTx Pharma develops RNA-based therapeutics using its FALCON platform, which conjugates short interfering RNAs with fatty acids to enhance cellular uptake and biodistribution beyond the liver. The company targets rare peripheral nervous system, muscle, and CNS disorders, expanding treatment options for previously untreatable genetic conditions.
- 0